Back to top
more

Avanos Medical (AVNS)

(Real Time Quote from BATS)

$23.71 USD

23.71
8,325

+0.17 (0.72%)

Updated Sep 13, 2024 10:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Hologic (HOLX) Surpasses Q2 Earnings and Revenue Estimates

Hologic (HOLX) delivered earnings and revenue surprises of 20.45% and 6.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Neogen (NEOG) Stock for Now

Investors are optimistic about Neogen (NEOG) owing to strong performance across its Animal Safety and Food Safety segments.

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

Quest Diagnostics (DGX) base business registers growth in the first quarter of 2023.

Integra's (IART) Q1 Earnings Match Estimates, Margins Contract

In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.

Edwards Lifesciences (EW) Q1 Earnings Top Estimates, '23 View Up

Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL Precision system in Europe.

Align Technology (ALGN) Q1 Earnings Beat, Margins Contract

Align Technology (ALGN) delivers better-than-expected revenues and earnings in the first quarter of 2023 but suffers significant foreign currency woes.

Boston Scientific (BSX) Q1 Earnings Beat, 2023 View Raised

Reported and organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in the reported quarter.

Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down

The year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments drove Thermo Fisher's (TMO) Q1 revenues.

LabCorp (LH) Q1 Earnings Miss Estimates, Margins Decline

The decline in COVID-19 PCR and antibody testing sales, the severe foreign exchange headwind and inflationary pressure hurt LabCorp's (LH) business performance in Q1.

Here's Why You Should Invest in Edwards Lifesciences (EW) Now

Investors are optimistic about Edwards Lifesciences (EW) on the increased adoption of its premium RESILIA technologies.

3 Reasons to Retain HealthEquity (HQY) Stock in Your Portfolio

Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Here is how Adaptive Biotechnologies (ADPT) and Avanos Medical (AVNS) have performed compared to their sector so far this year.

Neogen (NEOG) New Buyouts Aid Growth Amid Rise in Expenses

Neogen's (NEOG) performance of the Food Safety business is strong, driven by several long-term secular tailwinds.

Zimmer Biomet (ZBH) Hits 52-Week High: What's Driving It?

Investors are optimistic about Zimmer Biomet's (ZBH) continued business recovery.

Masimo's (MASI) New FDA Approval to Improve Patient Monitoring

Masimo's (MASI) receipt of the FDA's clearance for the Rad-G with Temperature is expected to support clinicians in almost any care scenario.

Intuitive Surgical (ISRG) Gains Following Q1 Earnings Beat

Intuitive Surgical's (ISRG) first-quarter results reflect healthy demand for procedures, partially offset by unfavorable currency. COVID-19 impacts procedure volume in China.

Elevance Health (ELV) Beats on Q1 Earnings, Hikes Profit View

Elevance Health's (ELV) first-quarter results reflect growing premiums stemming from rate increases.

Here's Why You Should Buy Boston Scientific (BSX) Stock

Investors are optimistic about Boston Scientific (BSX) owing to impressive growth in MedSurg market share.

Abbott's (ABT) Q1 Earnings Beat Estimates, Margins Down

Double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation contributed to Abbott's (ABT) Q1 revenues.

Myriad Genetics (MYGN) Gets Permit to Expand Tumor Testing

Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. states.

Insulet's (PODD) New Omnipod, Strategic Moves Drive Growth

Insulet (PODD) has been progressing well with respect to its four-pillar strategy, where the first two pillars include expanding access and awareness and delivering consumer-focused innovation.

Here's Why You Should Invest in Henry Schein (HSIC) Now

Investors are optimistic about Henry Schein (HSIC), led by the strong potential in the company's dental technology joint venture, Henry Schein One.

Abbott (ABT) Gets FDA Clearance for FreeStyle Libre 3 Reader

Abbott (ABT) receives the FDA clearance for a standalone reader to be used for the FreeStyle Libre 3 iCGM system.

UnitedHealth (UNH) Beats on Q1 Earnings, Ups EPS 2023 View

Strong membership growth and consistent management of medical and operating costs aid UnitedHealth's (UNH) UnitedHealthcare unit in the first quarter.

Bio-Rad (BIO) Rises 6.5% Since Q4 Earnings: What's Driving It?

Investors are optimistic about Bio-Rad's (BIO) strong global presence and stable solvency position.